Bristol Myers Squibb Stock Revenue Per Share

BMY Stock

USD 56.28 0.50 0.90%

Bristol Myers Squibb fundamentals help investors to digest information that contributes to Bristol Myers' financial success or failures. It also enables traders to predict the movement of Bristol Stock. The fundamental analysis module provides a way to measure Bristol Myers' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Bristol Myers stock.

		Last Reported	Projected for Next Year
	Revenue Per Share	21.75	22.84

Revenue Per Share is likely to rise to 22.84 in 2024.

This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Bristol Myers Squibb Company Revenue Per Share Analysis

Bristol Myers' Revenue per Share is a ratio of total revenue earned per one share of common stock over a single fiscal year. It is calculated by dividing sales revenue earned over 12 months by the average number of outstanding shares. Revenue used in the calculation of this ratio is typically recorded when cash or cash equivalents are exchanged for services or goods.

Current Bristol Myers Revenue Per Share

22.84

Most of Bristol Myers' fundamental indicators, such as Revenue Per Share, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Bristol Myers Squibb is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.

Bristol Revenue Per Share Driver Correlations

Understanding the fundamental principles of building solid financial models for Bristol Myers is extremely important. It helps to project a fair market value of Bristol Stock properly, considering its historical fundamentals such as Revenue Per Share. Since Bristol Myers' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Bristol Myers' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Bristol Myers' interrelated accounts and indicators.

	Total Assets	Total Stockholder Equity	Net Debt	Retained Earnings	Net Receivables	Good Will	Total Liab	Total Current Assets	Short Term Debt	Intangible Assets	Accounts Payable	Short Term Investments	Capital Stock	Common Stock	Long Term Debt	Treasury Stock	Property Plant Equipment	Current Deferred Revenue	Net Tangible Assets	Total Permanent Equity	Long Term Debt Total	Capital Surpluse	Deferred Long Term Liab	Long Term Investments	Short Long Term Debt	Cash And Equivalents	Net Invested Capital	Net Working Capital
Total Assets		0.89	0.98	-0.07	0.76	0.97	0.99	0.94	0.85	0.96	0.6	0.12	0.88	0.88	0.98	-0.76	0.83	0.44	-0.97	0.37	0.97	0.93	0.79	-0.5	-0.35	0.91	0.98	0.86
Total Stockholder Equity	0.89		0.84	0.13	0.5	0.82	0.85	0.76	0.73	0.93	0.62	0.36	0.81	0.81	0.85	-0.51	0.73	0.56	-0.87	0.28	0.81	0.73	0.82	-0.51	-0.31	0.83	0.89	0.79
Net Debt	0.98	0.84		-0.17	0.82	0.98	0.99	0.93	0.89	0.94	0.56	-0.02	0.91	0.91	0.99	-0.82	0.87	0.41	-0.99	0.44	0.99	0.97	0.76	-0.54	-0.37	0.93	0.98	0.85
Retained Earnings	-0.07	0.13	-0.17		-0.11	-0.03	-0.11	-0.05	-0.16	-0.13	0.44	0.49	-0.15	-0.15	-0.17	0.05	-0.07	-0.53	0.19	-0.45	-0.23	-0.26	-0.07	0.43	-0.13	-0.21	-0.19	-0.16
Net Receivables	0.76	0.5	0.82	-0.11		0.88	0.8	0.86	0.87	0.62	0.53	-0.15	0.81	0.81	0.8	-0.98	0.84	-0.05	-0.75	0.54	0.82	0.9	0.33	-0.35	-0.51	0.73	0.75	0.63
Good Will	0.97	0.82	0.98	-0.03	0.88		0.98	0.95	0.9	0.9	0.63	0.03	0.9	0.9	0.97	-0.88	0.88	0.27	-0.95	0.41	0.97	0.97	0.7	-0.47	-0.42	0.9	0.95	0.82
Total Liab	0.99	0.85	0.99	-0.11	0.8	0.98		0.96	0.87	0.94	0.61	0.05	0.9	0.9	0.99	-0.81	0.85	0.4	-0.98	0.4	0.98	0.95	0.77	-0.51	-0.37	0.93	0.97	0.86
Total Current Assets	0.94	0.76	0.93	-0.05	0.86	0.95	0.96		0.85	0.84	0.68	0.07	0.86	0.86	0.94	-0.86	0.81	0.23	-0.89	0.37	0.94	0.94	0.61	-0.4	-0.36	0.87	0.9	0.82
Short Term Debt	0.85	0.73	0.89	-0.16	0.87	0.9	0.87	0.85		0.82	0.53	0.05	0.84	0.84	0.87	-0.83	0.85	0.33	-0.87	0.57	0.87	0.9	0.6	-0.48	-0.43	0.87	0.88	0.75
Intangible Assets	0.96	0.93	0.94	-0.13	0.62	0.9	0.94	0.84	0.82		0.5	0.17	0.83	0.83	0.95	-0.62	0.78	0.61	-0.97	0.39	0.93	0.87	0.88	-0.63	-0.32	0.93	0.98	0.87
Accounts Payable	0.6	0.62	0.56	0.44	0.53	0.63	0.61	0.68	0.53	0.5		0.19	0.64	0.64	0.56	-0.61	0.6	-0.13	-0.54	-0.13	0.52	0.51	0.39	-0.01	-0.13	0.5	0.51	0.4
Short Term Investments	0.12	0.36	-0.02	0.49	-0.15	0.03	0.05	0.07	0.05	0.17	0.19		-0.04	-0.04	0.04	0.21	-0.1	0.19	-0.02	-0.17	-0.02	-0.09	0.24	0.09	-0.05	0.16	0.1	0.3
Capital Stock	0.88	0.81	0.91	-0.15	0.81	0.9	0.9	0.86	0.84	0.83	0.64	-0.04		1.0	0.9	-0.83	0.95	0.34	-0.9	0.46	0.91	0.92	0.64	-0.52	-0.35	0.86	0.9	0.78
Common Stock	0.88	0.81	0.91	-0.15	0.81	0.9	0.9	0.86	0.84	0.83	0.64	-0.04	1.0		0.9	-0.83	0.95	0.34	-0.9	0.46	0.91	0.92	0.64	-0.52	-0.35	0.86	0.9	0.78
Long Term Debt	0.98	0.85	0.99	-0.17	0.8	0.97	0.99	0.94	0.87	0.95	0.56	0.04	0.9	0.9		-0.8	0.85	0.43	-0.99	0.45	1.0	0.96	0.76	-0.58	-0.4	0.96	0.99	0.89
Treasury Stock	-0.76	-0.51	-0.82	0.05	-0.98	-0.88	-0.81	-0.86	-0.83	-0.62	-0.61	0.21	-0.83	-0.83	-0.8		-0.87	0.1	0.76	-0.41	-0.81	-0.9	-0.37	0.31	0.4	-0.7	-0.74	-0.59
Property Plant Equipment	0.83	0.73	0.87	-0.07	0.84	0.88	0.85	0.81	0.85	0.78	0.6	-0.1	0.95	0.95	0.85	-0.87		0.2	-0.86	0.54	0.86	0.89	0.64	-0.55	-0.47	0.8	0.84	0.72
Current Deferred Revenue	0.44	0.56	0.41	-0.53	-0.05	0.27	0.4	0.23	0.33	0.61	-0.13	0.19	0.34	0.34	0.43	0.1	0.2		-0.5	0.29	0.43	0.33	0.64	-0.51	0.1	0.51	0.53	0.53
Net Tangible Assets	-0.97	-0.87	-0.99	0.19	-0.75	-0.95	-0.98	-0.89	-0.87	-0.97	-0.54	-0.02	-0.9	-0.9	-0.99	0.76	-0.86	-0.5		-0.44	-0.98	-0.94	-0.83	0.6	0.35	-0.95	-0.99	-0.86
Total Permanent Equity	0.37	0.28	0.44	-0.45	0.54	0.41	0.4	0.37	0.57	0.39	-0.13	-0.17	0.46	0.46	0.45	-0.41	0.54	0.29	-0.44		0.49	0.52	0.17	-0.75	-0.76	0.51	0.48	0.45
Long Term Debt Total	0.97	0.81	0.99	-0.23	0.82	0.97	0.98	0.94	0.87	0.93	0.52	-0.02	0.91	0.91	1.0	-0.81	0.86	0.43	-0.98	0.49		0.98	0.74	-0.6	-0.39	0.95	0.98	0.89
Capital Surpluse	0.93	0.73	0.97	-0.26	0.9	0.97	0.95	0.94	0.9	0.87	0.51	-0.09	0.92	0.92	0.96	-0.9	0.89	0.33	-0.94	0.52	0.98		0.65	-0.56	-0.37	0.9	0.95	0.82
Deferred Long Term Liab	0.79	0.82	0.76	-0.07	0.33	0.7	0.77	0.61	0.6	0.88	0.39	0.24	0.64	0.64	0.76	-0.37	0.64	0.64	-0.83	0.17	0.74	0.65		-0.51	-0.11	0.76	0.8	0.78
Long Term Investments	-0.5	-0.51	-0.54	0.43	-0.35	-0.47	-0.51	-0.4	-0.48	-0.63	-0.01	0.09	-0.52	-0.52	-0.58	0.31	-0.55	-0.51	0.6	-0.75	-0.6	-0.56	-0.51		0.55	-0.65	-0.63	-0.6
Short Long Term Debt	-0.35	-0.31	-0.37	-0.13	-0.51	-0.42	-0.37	-0.36	-0.43	-0.32	-0.13	-0.05	-0.35	-0.35	-0.4	0.4	-0.47	0.1	0.35	-0.76	-0.39	-0.37	-0.11	0.55		-0.46	-0.38	-0.39
Cash And Equivalents	0.91	0.83	0.93	-0.21	0.73	0.9	0.93	0.87	0.87	0.93	0.5	0.16	0.86	0.86	0.96	-0.7	0.8	0.51	-0.95	0.51	0.95	0.9	0.76	-0.65	-0.46		0.96	0.94
Net Invested Capital	0.98	0.89	0.98	-0.19	0.75	0.95	0.97	0.9	0.88	0.98	0.51	0.1	0.9	0.9	0.99	-0.74	0.84	0.53	-0.99	0.48	0.98	0.95	0.8	-0.63	-0.38	0.96		0.89
Net Working Capital	0.86	0.79	0.85	-0.16	0.63	0.82	0.86	0.82	0.75	0.87	0.4	0.3	0.78	0.78	0.89	-0.59	0.72	0.53	-0.86	0.45	0.89	0.82	0.78	-0.6	-0.39	0.94	0.89

Click cells to compare fundamentals

Bristol Revenue Per Share Historical Pattern

Today, most investors in Bristol Myers Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Bristol Myers' growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's revenue per share growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Bristol Myers revenue per share as a starting point in their analysis.

Bristol Myers Revenue Per Share

Timeline

Revenue per share does not take into account any of company expenses and is helpful only when comparing relative sale figures within a given industry.

Competition

Predict Bristol Myers

Revenue Per Share Over Time

Bristol Common Stock Shares Outstanding

Common Stock Shares Outstanding

1.56 Billion

At this time, Bristol Myers' Common Stock Shares Outstanding is fairly stable compared to the past year.

Bristol Revenue Per Share Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Bristol Myers' direct or indirect competition against its Revenue Per Share to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Bristol Myers could also be used in its relative valuation, which is a method of valuing Bristol Myers by comparing valuation metrics of similar companies.

Bristol Myers is currently under evaluation in revenue per share category among its peers.

Bristol Myers ESG Sustainability

Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Bristol Myers' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Bristol Myers' managers, analysts, and investors.

Environmental

Governance

Social

Bristol Fundamentals

	Return On Equity	-0.31
	Return On Asset	0.0607
	Profit Margin	(0.15) %
	Operating Margin	0.18 %
	Current Valuation	156.44 B
	Shares Outstanding	2.03 B
	Shares Owned By Insiders	0.11 %
	Shares Owned By Institutions	79.75 %
	Number Of Shares Shorted	25.6 M
	Price To Earning	24.88 X
	Price To Book	6.60 X
	Price To Sales	2.38 X
	Revenue	45.01 B
	Gross Profit	36.38 B
	EBITDA	19.37 B
	Net Income	8.04 B
	Cash And Equivalents	9.12 B
	Cash Per Share	6.21 X
	Total Debt	41.46 B
	Debt To Equity	1.32 %
	Current Ratio	1.42 X
	Book Value Per Share	8.45 X
	Cash Flow From Operations	13.86 B
	Short Ratio	2.16 X
	Earnings Per Share	(3.58) X
	Price To Earnings To Growth	1.92 X
	Target Price	60.58
	Number Of Employees	34.1 K
	Beta	0.44
	Market Capitalization	113.13 B
	Total Asset	95.16 B
	Retained Earnings	28.77 B
	Working Capital	9.51 B
	Current Asset	10.41 B
	Current Liabilities	8.02 B
	Annual Yield	0.04 %
	Five Year Return	2.96 %
	Net Asset	95.16 B
	Last Dividend Paid	2.4

About Bristol Myers Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Bristol Myers Squibb's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Bristol Myers using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Bristol Myers Squibb based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Please read more on our fundamental analysis page.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

C	Citigroup
GM	General Motors
F	Ford Motor

Additional Tools for Bristol Stock Analysis

When running Bristol Myers' price analysis, check to measure Bristol Myers' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bristol Myers is operating at the current time. Most of Bristol Myers' value examination focuses on studying past and present price action to predict the probability of Bristol Myers' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bristol Myers' price. Additionally, you may evaluate how the addition of Bristol Myers to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC